Publikationen in Zusammenarbeit mit Forschern von Institut Universitari Dexeus (28)

2024

  1. Abstracts of the 34th World Congress on Ultrasound in Obstetrics and Gynecology, 15-18 September 2024, Budapest, Hungary

    Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, Vol. 64, pp. 121-122

  2. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

    Lung Cancer, Vol. 194

  3. Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial

    British Journal of Cancer, Vol. 130, Núm. 3, pp. 417-424

2023

  1. Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer (Scientific Reports, (2015), 5, 1, (17499), 10.1038/srep17499)

    Scientific Reports

  2. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer

    New England Journal of Medicine, Vol. 389, Núm. 6, pp. 504-513

2022

  1. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  2. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)

    Journal of Clinical Oncology, Vol. 71

2021

  1. COVID-19 in melanoma patients: Results of the Spanish Melanoma Group Registry, GRAVID study

    Journal of the American Academy of Dermatology, Vol. 84, Núm. 5, pp. 1412-1415

  2. Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 8

  3. First-line osimertinib in patients with epidermal growth factor receptor–mutant non–small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met

    European Journal of Cancer, Vol. 159, pp. 174-181

  4. Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study

    Journal of Clinical Medicine, Vol. 10, Núm. 13

  5. Placental growth factor testing in the management of late preterm preeclampsia without severe features: a multicenter, randomized, controlled trial

    American Journal of Obstetrics and Gynecology, Vol. 225, Núm. 3, pp. 308.e1-308.e14

  6. Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy

    Clinical Cancer Research, Vol. 27, Núm. 21, pp. 5878-5890

  7. Three-dimensional ultrasonography for advanced neurosonography (neurosofe-3D): Validation of a brain volume acquisition guideline

    Acta Obstetricia et Gynecologica Scandinavica, Vol. 100, Núm. 1, pp. 84-90

2019

  1. Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer

    Journal of Thoracic Oncology, Vol. 14, Núm. 2, pp. 304-310

  2. Two decades of embryonic stem cells: A historical overview

    Human Reproduction Open, Vol. 2019, Núm. 1

2017

  1. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

    Journal of the National Cancer Institute, Vol. 109, Núm. 9

2016

  1. Three dimensional ultrasonography for advanced neurosonography (Neurosofe-3d). Analysis of acquisition-related factors influencing the quality of the brain volumes

    Prenatal Diagnosis, Vol. 36, Núm. 11, pp. 1054-1060

2015

  1. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

    Scientific Reports, Vol. 5

2013

  1. Changes in acromegaly treatment over four decades in Spain: Analysis of the Spanish Acromegaly Registry (REA)

    Pituitary, Vol. 16, Núm. 1, pp. 115-121